List of Excipients in Branded Drug MRESVIA

« Back to Dashboard

MRESVIA Excipient Strategy and Commercial Opportunities in mRNA-RSV Vaccines

Last updated: September 26, 2026

MRESVIA is Moderna’s mRNA-1345 respiratory syncytial virus vaccine for adults aged 60 years and older. Its excipient system is built around a four-lipid nanoparticle, an acidic acetate buffer, tromethamine-based pH control, sucrose for stabilization, and water for injection. The commercial opportunity is concentrated in GMP lipid supply, lipid nanoparticle manufacturing, sterile fill-finish, cold-chain services, analytical testing, and next-generation thermostable formulations.

What is the MRESVIA formulation and excipient composition?

MRESVIA contains 50 micrograms of RSV prefusion F protein mRNA in a 0.5 mL intramuscular dose. The mRNA is encapsulated in a lipid nanoparticle, or LNP, that uses the same broad excipient architecture established in Moderna’s COVID-19 vaccine platform.

Component	Function in MRESVIA	Commercial relevance
mRNA encoding RSV prefusion F protein	Active pharmaceutical ingredient	Requires sequence integrity, capped RNA quality, and control of truncated transcripts
SM-102	Ionizable lipid	Core LNP component; high-value specialty lipid
Cholesterol	Structural lipid	Supports particle stability and membrane organization
DSPC	Phospholipid	Provides LNP structural integrity
PEG2000-DMG	PEGylated lipid	Controls particle size, aggregation, and surface properties
Tromethamine	Buffer and pH-control agent	Supports formulation stability
Tromethamine hydrochloride	Buffer component	Helps maintain target pH and ionic conditions
Acetic acid	pH adjustment	Supports buffer control
Sodium acetate trihydrate	Acetate buffer component	Controls formulation pH and osmolality
Sucrose	Cryo- and lyoprotectant	Limits stress during freezing and thawing
Water for injection	Vehicle	Parenteral-grade formulation medium

MRESVIA does not use an aluminum adjuvant. Its immunogenicity depends on the mRNA-LNP system rather than a conventional protein-antigen adjuvant. The formulation is preservative-free and supplied as a sterile injectable product. The FDA prescribing information identifies the listed lipids and buffer components as inactive ingredients. [1]

How does MRESVIA’s lipid nanoparticle excipient strategy work?

The lipid system uses complementary functions rather than a single stabilizing excipient.

SM-102

SM-102 is the ionizable lipid. At acidic pH during LNP production, it becomes positively charged and associates with the negatively charged mRNA. At physiological pH, its charge is reduced, which helps limit persistent electrostatic interactions and supports tolerability.

SM-102 is the most strategically important excipient in the formulation. It is not a conventional commodity excipient. Supply requires specialized synthesis, impurity control, analytical characterization, and regulatory documentation. Commercial opportunities include:

• GMP-scale SM-102 synthesis
• Qualified secondary-source manufacturing
• Intermediate and impurity reference standards
• Stable, validated lipid storage and shipping
• Process development for higher encapsulation efficiency
• Alternative ionizable-lipid screening

The supply chain is more constrained than for cholesterol, sucrose, acetate, or tromethamine. A supplier with a validated process and regulatory history can capture value through qualification costs and switching barriers.

Cholesterol

Cholesterol improves LNP packing and membrane structure. It is widely available relative to SM-102, but pharmaceutical-grade material requires control of purity, oxidation products, residual solvents, and bioburden.

The opportunity is less likely to be molecule-specific exclusivity and more likely to involve:

• GMP-grade cholesterol supply
• Low-oxidation material
• Consistent particle-size performance
• Documentation for viral and adventitious-agent controls
• Regional manufacturing redundancy

DSPC

DSPC, or 1,2-distearoyl-sn-glycero-3-phosphocholine, is a saturated phospholipid used to support LNP structure. It is a specialized pharmaceutical lipid rather than a typical formulation excipient in small-molecule products.

DSPC suppliers can compete on:

• Lot consistency
• Oxidative and hydrolytic impurity control
• Particle-size reproducibility
• Supply continuity
• Scale-up support for commercial LNP production

DSPC is less differentiated than SM-102, but a change in supplier can affect LNP performance and may require comparability work.

PEG2000-DMG

PEG2000-DMG is a PEGylated lipid that helps control particle size, aggregation, and colloidal behavior. Its concentration is usually low, but it has a disproportionate impact on LNP surface characteristics.

Commercial risks include PEG-related immunogenicity concerns, accelerated clearance after repeated exposure, and potential limitations in repeat-dose applications. Commercial opportunities include:

• Alternative PEG-lipid architectures
• Cleavable PEG-lipids
• Reduced-PEG formulations
• Non-PEG steric stabilizers
• LNP systems designed for repeated annual administration

For an RSV vaccine used in older adults, PEG2000-DMG is a formulation-performance component. For future products requiring repeated dosing or chronic administration, it is also a potential design constraint.

What buffer and stabilizer system does MRESVIA use?

MRESVIA uses a combined acetate and tromethamine system with sucrose. Each component addresses a separate formulation problem.

The acetate components support pH control. Tromethamine and tromethamine hydrochloride provide additional buffering capacity. Sucrose helps protect the LNP and mRNA during frozen storage and thawing.

This excipient approach has several advantages:

1. It avoids an adjuvant.
2. It uses established parenteral formulation materials.
3. It supports frozen storage and thawing.
4. It is compatible with sterile injectable manufacturing.
5. It limits the number of novel formulation components requiring regulatory justification.

The tradeoff is that the product remains dependent on a cold-chain distribution model. The FDA label requires frozen storage and controlled handling after thawing. The precise storage window depends on the labeled temperature condition and packaging configuration. [1]

What excipient-related manufacturing barriers affect MRESVIA?

The principal barrier is not the cost of common excipients. It is the integrated control of lipid quality, mRNA quality, nanoparticle assembly, and sterile filling.

Lipid raw-material control

Each lipid can affect particle size, encapsulation efficiency, potency, and stability. Relevant controls include:

• Identity and assay
• Related substances
• Residual solvents
• Water content
• Peroxide and oxidation products
• Hydrolysis products
• Particle and aggregate effects
• Microbial and endotoxin control

A supplier must support a complete chemistry, manufacturing, and controls package. Pharmaceutical-grade certification alone is insufficient if the lipid is used in a complex LNP process.

LNP process control

Commercial LNP production typically depends on controlled mixing of an acidic aqueous mRNA phase with an ethanol-based lipid phase. The process must control:

• Flow rates
• Mixing energy
• pH
• Ethanol content
• Lipid-to-RNA ratio
• Encapsulation efficiency
• Particle-size distribution
• Polydispersity
• Residual solvent removal
• Buffer exchange
• Concentration and sterile filtration

Small changes in lipid ratio or mixing conditions can alter potency and stability. This creates an opportunity for equipment suppliers, process-development firms, and contract development and manufacturing organizations, or CDMOs.

Analytical testing

MRESVIA-type products require more extensive testing than standard small-molecule injectables. Commercially relevant assays include:

• mRNA sequence identity
• 5' capping efficiency
• Poly(A) tail characterization
• RNA integrity
• Double-stranded RNA impurities
• Encapsulation efficiency
• Particle size and polydispersity
• Lipid identity and content
• Residual DNA and protein
• Sterility and endotoxin
• In vitro translation or potency
• Subvisible and visible particulates

Contract laboratories with validated mRNA and LNP methods can obtain recurring testing revenue from release, stability, comparability, and post-approval manufacturing changes.

What commercial opportunities exist in the MRESVIA excipient supply chain?

The strongest opportunities sit upstream and adjacent to the finished vaccine.

Opportunity	Demand driver	Entry barrier	Revenue profile
SM-102 production	Core ionizable lipid requirement	High	High-value, qualification-driven
DSPC and PEG2000-DMG	LNP component supply	Moderate to high	Recurring specialty-material sales
Pharmaceutical cholesterol	Structural LNP lipid	Moderate	Larger-volume, lower-margin
LNP CDMO services	Outsourcing and capacity constraints	High	Development fees plus manufacturing revenue
Sterile fill-finish	Injectable product supply	High	Capacity-constrained recurring revenue
mRNA analytical testing	Release and stability requirements	High	Fee-for-service and method licensing
Frozen logistics	Product storage profile	Moderate	Recurring distribution revenue
Stabilizing formulation technology	Pressure to reduce cold-chain cost	High	Platform licensing and product partnerships
Alternative PEG-lipid systems	Repeat-dose and tolerability needs	High	Patent and licensing potential
Single-use mixing systems	LNP process scale-up	Moderate to high	Equipment and consumables revenue

The most defensible commercial positions are those that combine a material with process know-how. A generic supply contract for cholesterol has limited differentiation. A validated ionizable-lipid process, a qualified LNP manufacturing platform, or a proprietary thermostability solution has greater strategic value.

How does MRESVIA compare with competing RSV vaccines?

MRESVIA competes with protein-based RSV vaccines, including GSK’s Arexvy and Pfizer’s Abrysvo. These products use different antigen, adjuvant, and manufacturing systems.

Product	Sponsor	Platform	Key formulation distinction
MRESVIA	Moderna	mRNA-LNP	Uses SM-102, cholesterol, DSPC, PEG2000-DMG, buffers, and sucrose
Arexvy	GSK	Recombinant prefusion F protein	Uses a protein antigen with an adjuvant system
Abrysvo	Pfizer	Recombinant prefusion F protein	Protein-based, non-mRNA approach

MRESVIA’s excipient strategy has platform advantages. It avoids recombinant protein production and a separate adjuvant system. It also allows sequence changes without redesigning the antigen-production process in the same manner as a protein vaccine.

Its disadvantages include:

• Greater sensitivity to manufacturing conditions
• More demanding analytical characterization
• Dependence on specialized lipids
• Frozen storage requirements
• Potential public and regulatory scrutiny concerning LNP components
• Higher process-comparability burden when changing lipid sources or ratios

Protein-based competitors may have simpler raw-material procurement and broader room-temperature handling options. MRESVIA has a stronger strategic fit with Moderna’s existing mRNA manufacturing infrastructure.

What patent and regulatory issues affect MRESVIA excipients?

MRESVIA is regulated as a biologic vaccine under a Biologics License Application, not as a conventional small-molecule drug. It is therefore not expected to have a conventional Orange Book listing comparable to an NDA product. Patent disputes involving the product are more likely to concern mRNA chemistry, LNP composition, delivery technology, manufacturing processes, or platform rights than traditional formulation patents listed in the Orange Book. [1][2]

Excipient and LNP patent exposure

Potentially relevant patent categories include:

• Ionizable lipid structures
• Lipid combinations and molar ratios
• mRNA encapsulation methods
• Microfluidic or controlled-mixing processes
• PEG-lipid use in nucleic-acid delivery
• LNP size and surface-charge specifications
• Buffer systems for mRNA-LNP products
• Freeze-thaw stabilization
• Manufacturing and purification methods

A supplier selling SM-102 or another lipid must assess both composition-of-matter rights and use claims. A material may be commercially available yet still create freedom-to-operate issues when used in a particular LNP, disease indication, or manufacturing process.

Orange Book and Paragraph IV status

MRESVIA does not fit the standard generic-drug pathway associated with Orange Book-listed patents and Paragraph IV certifications. A conventional ANDA challenge is not the expected competitive route for a biologic vaccine. Follow-on competition would require a biologics pathway, manufacturing capability, and sufficient analytical and clinical support.

Biosimilar risk

Biosimilar risk is limited in the near term because MRESVIA is a complex mRNA-LNP product with multiple critical quality attributes. A follow-on product would need to establish comparability across:

• mRNA sequence and structure
• LNP composition
• Particle size
• Encapsulation
• Potency
• Impurity profile
• Stability
• Immunogenicity and safety

The principal barrier is not the availability of the individual excipients. It is reproducing the complete product and process within the applicable regulatory framework.

When does MRESVIA lose exclusivity?

MRESVIA’s commercial exclusivity is determined by a combination of biologic regulatory exclusivity, patents, manufacturing know-how, and market access. The FDA approved MRESVIA in May 2024 for prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older. [1]

The U.S. biologics framework generally provides 12 years of reference-product exclusivity from first licensure under the Biologics Price Competition and Innovation Act, subject to statutory rules and any applicable pediatric exclusivity. [3] Patent protection may extend beyond or expire before that period, depending on the relevant patent families.

A precise MRESVIA patent-expiration date cannot be assigned solely from the product name. Product-specific analysis requires review of the applicable patent families, terminal disclaimers, patent-term adjustments, continuations, and any later-issued patents covering formulation or manufacturing.

What formulation improvements could create commercial opportunities?

The highest-value formulation opportunities concern distribution cost, repeat dosing, and manufacturing robustness.

Improved thermal stability

A formulation that extends refrigerated or room-temperature stability could reduce frozen-storage requirements. Potential approaches include:

• Alternative sugar systems
• Amino-acid or polyol stabilizers
• Lyophilized LNP formulations
• Spray-dried or powder presentations
• Modified lipid compositions
• Improved container-closure systems

Any change would require evidence that particle size, encapsulation, RNA integrity, potency, and sterility remain within specifications.

Reduced PEG dependence

A lower-PEG or PEG-free LNP could address repeat-dose and tolerability concerns. The challenge is preserving colloidal stability and manufacturing consistency. Suppliers with non-PEG surface-stabilizing lipids could license formulation technology to vaccine developers.

Lower-dose formulations

Higher potency per microgram could reduce lipid consumption, manufacturing time, and dose cost. This opportunity depends on improving mRNA translation, particle delivery, and antigen expression without increasing reactogenicity.

Prefilled and administration-ready presentations

Pre-filled syringes or simplified thaw-and-use presentations could reduce pharmacy handling. The commercial value would depend on device compatibility, stability in the final container, extractables and leachables, and dose-volume control.

What generic launch risks exist for MRESVIA?

The conventional generic-launch risk is low compared with small-molecule drugs. The more realistic risks are:

1. Competing RSV vaccines gaining preferred formulary or public-health positioning.
2. A future mRNA RSV vaccine using a different LNP platform.
3. Improved thermostability reducing MRESVIA’s logistics advantage.
4. A lower-cost protein vaccine expanding access.
5. Follow-on biologic development after key patent and regulatory barriers decline.
6. Manufacturing disruptions involving SM-102 or other specialized lipids.
7. Safety or tolerability findings that reduce repeat vaccination demand.

For investors and suppliers, market-share risk may arrive before direct biosimilar substitution. The commercial question is whether MRESVIA can maintain demand across annual or periodic RSV vaccination campaigns while competing products use different storage, adjuvant, and procurement models.

Key Takeaways

• MRESVIA uses an mRNA-LNP system containing SM-102, cholesterol, DSPC, PEG2000-DMG, acetate and tromethamine buffers, sucrose, and water for injection.
• SM-102 is the most strategically valuable excipient because it is specialized, process-sensitive, and central to product performance.
• The best commercial opportunities are in GMP lipid supply, LNP CDMO manufacturing, analytical testing, sterile fill-finish, and cold-chain services.
• MRESVIA is regulated as a biologic and is not expected to follow the standard Orange Book and Paragraph IV generic pathway.
• Biosimilar substitution is technically difficult because the product’s critical quality attributes depend on the complete mRNA-LNP process.
• Formulation innovation is most likely to target thermostability, reduced PEG dependence, lower dose, and simpler administration.
• MRESVIA’s key competitive risk is not an immediate conventional generic launch. It is displacement by protein-based RSV vaccines, improved mRNA formulations, or future LNP platforms.

FAQs About MRESVIA Excipient Strategy

What is the most important excipient in MRESVIA?

SM-102 is the most commercially important excipient because it is the ionizable lipid that enables mRNA encapsulation and LNP delivery.

Does MRESVIA contain an aluminum adjuvant?

No. MRESVIA uses an mRNA-LNP delivery system rather than an aluminum-based adjuvant.

Does MRESVIA contain PEG?

Yes. MRESVIA contains PEG2000-DMG, a PEGylated lipid used to control LNP surface properties and aggregation.

Can a manufacturer substitute another lipid for SM-102?

Not without substantial formulation development, analytical comparability, process validation, and regulatory review. A lipid substitution can change particle size, encapsulation, potency, stability, and tolerability.

Is MRESVIA subject to a Paragraph IV patent challenge?

MRESVIA is a biologic vaccine, so a conventional ANDA Paragraph IV challenge is not the expected pathway. Competitive entry would more likely involve a biosimilar or other follow-on biologic strategy, subject to patent and regulatory requirements.

References

1. U.S. Food and Drug Administration. (2024). MRESVIA (mRNA-1345) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

3. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001-7003.